BC Platforms Strengthens Global Presence Through Medexprim Acquisition

BC Platforms Expands Access to Real-World Data Assets with Medexprim Acquisition

BC Platforms, a global leader in life sciences data networks, has acquired Medexprim to enhance its capabilities in providing secure access to real-world clinical and imaging data assets across Europe.

The deal, the financial details of which remain undisclosed, strengthens BC Platforms’ position in serving biopharma partners globally.

Medexprim’s Role in Bridging Academic Hospitals and Industry

Under the leadership of CEO Romain Cazavan, Medexprim plays a pivotal role in building connections between European academic hospitals and entities in life sciences, AI, and medical devices.

The company, based in Toulouse, France, and Paris, provides regulatory-grade, multimodal, and multicentric datasets. These datasets aid in addressing the complexities of personalized medicine, supporting the quest for individualized treatments for each patient.

Expertise and Presence of Medexprim

Medexprim boasts a team of 35 industry experts and operates with a center of excellence for R&D in Toulouse, France, and a commercial headquarters in Paris. The company’s presence and expertise make it a valuable addition to BC Platforms’ portfolio.

BC Platforms’ Global Leadership in Personalized Medicine

With CEO Tero Silvola at the helm, BC Platforms is known for its global leadership in constructing data networks for the life sciences industry.

The company’s technology platforms facilitate personalized medicine, speeding up the translation of innovations into clinical practice. BC Platforms has a significant global presence, with headquarters in Zurich, Switzerland, and operations in Espoo, Finland, Singapore, London, UK, Lund, Sweden, Toulouse, France, and Boston, USA.

Continued Expansion: Recent Addition of 4Pharma

This acquisition follows BC Platforms’ strategic move to include 4Pharma in its portfolio, further expanding its reach and capabilities in the European market.